When was MacroGenics founded?

MacroGenics was founded in 2000 and raised its 1st funding round 1 year after it was founded.

Where is MacroGenics located?

MacroGenics is headquartered in Rockville, United States. It is registered at Rockville, Maryland.

How many employees does MacroGenics have?

As of Sep 30, 2026, the latest employee count at MacroGenics is 328.

Is MacroGenics a funded company?

MacroGenics is a funded company, having raised a total of $126M across 11 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 25, 2001.

When was the latest funding round of MacroGenics?

MacroGenics' latest funding was a $***** Post IPO round on Mar 20, 2019, with participation from 1 investor.

What is the annual revenue of MacroGenics?

Annual revenue of MacroGenics is between $100M and $500M as on Dec 31, 2025

Where does MacroGenics rank among its competitors?

MacroGenics ranks 115th amongst 3458 active competitors, of which 1160 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of MacroGenics?

MacroGenics' top competitors include Jazz Pharmaceuticals, BeiGene and argenx. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

MacroGenics - 2026 Company Profile, Funding, Competitors & Financials

MacroGenics is a public company based in Rockville (United States), founded in 2000. It operates as a Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease. MacroGenics has raised $126M in funding from Ventures West and Nextech Venture. The company has 3458 active competitors, including 1160 funded and 823 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and argenx.

Company Details

Developer of novel biologics for the treatment of autoimmune disorders, cancer, and infectious disease. The company is developing immune-based products, including monoclonal antibodies and vaccines to prevent infections in healthy individuals. The company’s Fc engineering technology enables to the improvement of antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. Its lead candidate for cancer is Margetuximab, which is an Fc-optimized monoclonal antibody that targets the human epidermal growth factor receptor 2, or HER2. HER2 is expressed by tumor cells in the breast, gastroesophageal, bladder, and other forms of solid tumor cancers, making it a key marker for biologic therapy.

Website: macrogenics.com
Social
Registered Address: Rockville, Maryland

Key Metrics

Founded Year

2000

Location

Rockville, United States

Stage

Public

Total Funding

$126M in 11 rounds

Latest Funding Round

Post IPO, Mar 20, 2019, $*****

Investors

Ventures West & 30 more

Ranked

115^th among 3458 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2025

Employee Count

328 as on Sep 30, 2026

Investment & Acquisitions

Raven Biotechnologies

Similar Companies

Jazz Pharmaceuticals & 3187 more

Exit Details

Public

View MacroGenics' full profile

MacroGenics is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Macrogenics Inc CIN: 1125345 , United States, Active	Aug 13, 2000	$100M - $500M (As on Dec 31, 2025)	-	-
Macrogenics, Inc. CIN: 06-1591613 , United States, Active	Dec 31, 1999	-	339 (As on Dec 31, 2023)	-
MACROGENICS CIN: 61591613 , United States, Active	Dec 26, 999	-	341 (As on Dec 31, 2024)	-

MacroGenics got listed on Oct 10, 2013.

Click here to take a look at MacroGenics's IPO in detail

MacroGenics has raised a total funding of $126M over 11 rounds. Its first funding round was on Sep 25, 2001. Its latest funding round was a Post IPO round on Mar 20, 2019 for $*****. 1 investor participated in its latest round. MacroGenics has 31 institutional investors.

Here is the list of recent funding rounds of MacroGenics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 20, 2019	1663341	Post IPO	4459383	5891614	8018666	6536212
Jan 28, 2011	6955024	Series D	3879337	8476062	1418999	5257911
Jul 15, 2010	6082859	Grant (prize money)	5170832	4863366	9935087	NIH

Access funding benchmarks and valuations. Sign up today!

View details of MacroGenics's funding rounds and investors

MacroGenics' employee count trend

MacroGenics has 328 employees as of Sep 26. Here is MacroGenics's employee count trend over the years:

Uncover MacroGenics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MacroGenics include Jazz Pharmaceuticals, BeiGene and argenx. Here is the list of Top 10 competitors of MacroGenics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
7th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
115th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	BB Biotech, Saints Capital & 29 others	59/100